GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » Loans Receivable

Marker Therapeutics (FRA:GX1) Loans Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Marker Therapeutics Loans Receivable?

Marker Therapeutics's Loans Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


Marker Therapeutics Loans Receivable Historical Data

The historical data trend for Marker Therapeutics's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics Loans Receivable Chart

Marker Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Marker Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Marker Therapeutics Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Marker Therapeutics Loans Receivable Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Marker Therapeutics (FRA:GX1) Business Description

Traded in Other Exchanges
Address
4551 Kennedy Commerce Drive, Houston, TX, USA, 77032
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Marker Therapeutics (FRA:GX1) Headlines

No Headlines